Breaking the resistance barrier: emerging nanotherapeutic strategies targeting tumor plasticity, stemness, and microenvironmental protection
5 affiliations
- 1Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas Knowledge City, Adamas University
- 2Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior
- 3Department of Pharmaceutical Sciences, Innovative Group of Colleges
- 4Department of Pharmacy Practice, Saveetha College of Pharmaceutical Sciences, Saveetha Institute of Medical and Technical Sciences (SIMATS), Deemed University
- 5Department of Pharmacology, Saveetha College of Pharmaceutical Sciences, Saveetha Institute of Medical and Technical Sciences (SIMATS), Deemed University
Abstract
Therapeutic resistance is a significant obstacle to sustained responses in solid tumors, as resistant phenotypes are linked to complex and interdependent genetic, epigenetic, metabolic, cellular and microenvironmental adaptations. The plasticity of tumors, the cancer stemness, the rewiring of oncogenic pathways, the targeting of DNA damage responses, drug resistance, metabolic flexibility and apoptosis resistance can all play their part in keeping the tumor-cell alive under therapeutic stress. Hypoxia, cancer-associated fibroblasts, vasculature, extracellular matrix remodeling, tumor-associated macrophages, regulatory T cells, extracellular vesicles signaling and hostile tumor niches are other mechanisms that reinforce these processes. This review explores the development of the use of nanomedicine in overcoming resistance mechanisms other than pharmacokinetic enhancement. Targeted delivery, resistance re-sensitization, modulation of the tumor microenvironment, metabolic intervention, delivery of nucleic acids, combination and sequential therapy, and activation of alternative regulated cell-death pathways are reviewed for polymeric, lipid, biomimetic, inorganic, hybrid and stimuli-responsive nanoplatforms. The dynamic interplay between tumor plasticity, drug-tolerant persister states, stem-like populations and stable resistance is emphasized. The review also delves into precision nanomedicine combining biomarkers, multi-omics, patient-derived organoids, patient-derived models, tumor-on-chip systems, and AI-driven formulation and selection. Finally, translational barriers such as tumor accumulation, protein corona, safety, manufacture reproducibility, scalability, regulatory complexity and patient heterogeneity are taken into account. Finally, mechanism-driven and adaptive nanomedicine may offer a rational approach to enhancing resistance management, which need to be thoroughly validated in relevant models.
Related
- Molecular and microenvironmental networks driving tumor dormancy: pathological mechanisms and emerging clinical strategies
- Emerging therapeutic strategies for medication-related osteonecrosis of the jaw: From microenvironmental modulation to precision medicine (Review).
- FOXM1 as a candidate dosage rheostat and state selector in breast cancer: linking multilevel regulation to adaptive plasticity and therapy resistance
- Aging concomitantly reduces skeletal muscle proteome plasticity and hypertrophic responses to resistance training in male adults
- Epigenetic and metabolic plasticity of tumor cells in immunotherapy resistance
BibTeX
@article{chettupalli2026breaking,
title = {{Breaking the resistance barrier: emerging nanotherapeutic strategies targeting tumor plasticity, stemness, and microenvironmental protection}},
author = {Ananda Kumar Chettupalli and Priyanshu Pathak and Ankita Singh and Divya Amaravadi and Sudha Murugesan},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.2006749},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.2006749/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Breaking the resistance barrier: emerging nanotherapeutic strategies targeting tumor plasticity, stemness, and microenvironmental protection
AU - Ananda Kumar Chettupalli
AU - Priyanshu Pathak
AU - Ankita Singh
AU - Divya Amaravadi
AU - Sudha Murugesan
PY - 2026
DA - 2026/11/09
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.2006749
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.2006749/full
AB - Therapeutic resistance is a significant obstacle to sustained responses in solid tumors, as resistant phenotypes are linked to complex and interdependent genetic, epigenetic, metabolic, cellular and microenvironmental adaptations. The plasticity of tumors, the cancer stemness, the rewiring of oncogenic pathways, the targeting of DNA damage responses, drug resistance, metabolic flexibility and apoptosis resistance can all play their part in keeping the tumor-cell alive under therapeutic stress. Hypoxia, cancer-associated fibroblasts, vasculature, extracellular matrix remodeling, tumor-associated macrophages, regulatory T cells, extracellular vesicles signaling and hostile tumor niches are other mechanisms that reinforce these processes. This review explores the development of the use of nanomedicine in overcoming resistance mechanisms other than pharmacokinetic enhancement. Targeted delivery, resistance re-sensitization, modulation of the tumor microenvironment, metabolic intervention, delivery of nucleic acids, combination and sequential therapy, and activation of alternative regulated cell-death pathways are reviewed for polymeric, lipid, biomimetic, inorganic, hybrid and stimuli-responsive nanoplatforms. The dynamic interplay between tumor plasticity, drug-tolerant persister states, stem-like populations and stable resistance is emphasized. The review also delves into precision nanomedicine combining biomarkers, multi-omics, patient-derived organoids, patient-derived models, tumor-on-chip systems, and AI-driven formulation and selection. Finally, translational barriers such as tumor accumulation, protein corona, safety, manufacture reproducibility, scalability, regulatory complexity and patient heterogeneity are taken into account. Finally, mechanism-driven and adaptive nanomedicine may offer a rational approach to enhancing resistance management, which need to be thoroughly validated in relevant models.
SN - 2234-943X
ER -